Key Highlights
- Fully remote lab testing now available via Locke Bio
- Speeds up diagnoses and improves treatment accuracy
- Available to enterprise clients in all 50 U.S. states
- Supports hormone therapy and chronic disease care
- Built-in compliance for secure, seamless integration
Source: PR Newswire
Notable Quotes
- “By adding imaware’s lab testing, we’re not just enhancing telehealth—we’re redefining what’s possible in digital medicine.” — Cathy Tie, Founder & CEO at Locke Bio
- “This partnership removes friction from the diagnostic process, allowing patients and providers to focus on better health outcomes.” — Brodie Flanders, CEO at imaware
Why This Matters
This integration marks a major milestone in digital healthcare, enabling telehealth platforms to deliver comprehensive, lab-validated treatment remotely. By eliminating the need for in-person diagnostics, Locke Bio and imaware are accelerating the transition to a more efficient, accessible, and scalable healthcare system. This positions Locke Bio as a leader in digital-first healthcare, closing the gap between online convenience and clinical-grade care.
